Chinese Market Offers New Life to Many Drugs
Excerpt from Article:
[...] But the new trend also raises the question of whether China has become a dumping ground for inferior drugs.
I. Glenn Cohen, a Harvard Law School professor who studies medical ethics, said that because of differences in regulatory standards it isn't unusual or unlawful for a company to get a drug approved in one jurisdiction and not another.
For one thing, in China a drug doesn't have to prove superiority over existing drugs--a major hurdle in the U.S., where 90% of candidates get dropped in the clinical-trial process. [...]fda i. glenn cohen medical tourism pharmaceuticals